Welcome to our dedicated page for COMPASS Pathways plc SEC filings (Ticker: CMPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
COMPASS Pathways plc filings document the regulatory record for a biotechnology company developing COMP360, a proprietary synthetic psilocybin formulation for mental health indications including treatment-resistant depression. Current reports disclose financial results, clinical and regulatory updates, investor presentation materials, and material agreements tied to debt facilities and securities offerings.
Proxy and other filings cover annual general meeting matters, board structure, committee assignments, compensation arrangements, and shareholder voting procedures. Capital-structure disclosures include American Depositary Shares, ordinary shares, pre-funded warrants, registration statement references, underwriting terms, and loan and security agreement amendments.
COMPASS Pathways plc (CMPS) submitted a notice of proposed sales of American Depositary Shares. The filing lists 26,000 ADS to be sold through Fidelity Brokerage Services LLC on 08/10/2026, following a stock option exercise by the issuer. It also reports that Annalisa Jenkins sold 83,771 ADS for $1,149,153.55 on 08/07/2026 during the prior three months.
COMPASS Pathways plc Chief Executive Officer Kabir Nath reported an insider transaction involving 5,962 Ordinary Shares on August 3, 2026. These shares were withheld by the issuer at $11.25 per share to satisfy tax withholding obligations upon vesting of restricted share units, rather than sold in the open market. After this tax-withholding disposition, Nath directly holds 361,028 Ordinary Shares, which may be represented by an equal number of American Depositary Shares.
Compass Pathways plc filed an automatic Form S‑3 shelf registration as a well‑known seasoned issuer, enabling flexible primary offerings of an indeterminate amount of ordinary shares (including ADSs), debt securities, warrants, and units, as well as secondary resales. A separate resale prospectus covers the potential resale of up to 10,649,700 ordinary shares or ADSs by named selling security holders, from which Compass will not receive proceeds. As of June 30, 2026, ordinary shares outstanding were 135,722,306, with 23,848,829 pre‑funded warrants outstanding, each exercisable for one ADS at $0.0001 per ADS. The company highlights advanced clinical progress for its COMP360 psilocybin program in treatment‑resistant depression, including positive Phase 3 results, FDA rolling review of its NDA, and award of a National Priority Voucher, and is initiating a Phase 2b/3 trial in PTSD.
Compass Pathways plc reported results for the three and six months ended June 30, 2026 and outlined clinical, regulatory and launch progress for COMP360 psilocybin in treatment-resistant depression (TRD) and PTSD. Two positive Phase 3 TRD trials showed rapid onset and durable benefit through at least 6 months, with 39% of participants in COMP006 and 25% in COMP005 achieving a ≥25% reduction in MADRS at Week 6 and maintaining benefit on average to Week 26. A rolling New Drug Application submission for COMP360 in TRD is underway, with final modules expected in the fourth quarter of 2026 and potential U.S. commercial launch targeted for the first half of 2027, subject to FDA approval and DEA and state rescheduling.
Research and development expenses were $29.2 million in Q2 2026, slightly below Q2 2025, while general and administrative expenses rose to $23.2 million, driven by commercial preparedness. Net loss for Q2 2026 widened to $253.8 million (loss of $1.88 per share), primarily due to a $205.6 million non-cash loss from fair value changes in warrant liabilities. Cash and cash equivalents were $433.3 million and debt $50.7 million as of June 30, 2026, and the company expects its cash to fund operations into 2028.
Compass Pathways plc reported a net loss of $162.6 million for the six months ended June 30, 2026, compared with $56.3 million a year earlier. Results were heavily affected by a $74.7 million year‑to‑date non‑cash loss from fair value changes in warrant liabilities and higher general and administrative spending tied to commercial preparation.
Operating expenses for the six months were $95.3 million, including research and development of $55.7 million and general and administrative of $39.6 million. Cash and cash equivalents grew to $433.3 million from $149.6 million at year‑end, driven by equity offerings, warrant exercises and additional Hercules term debt; the company states this should fund operating and capital needs into 2028.
Total assets were $504.6 million, liabilities $420.0 million and shareholders’ equity improved from a deficit to $84.5 million, despite sizable warrant liabilities of $337.5 million. Clinically, both pivotal Phase 3 TRD trials (COMP005 and COMP006) met primary endpoints with statistically significant, clinically meaningful MADRS reductions, supporting an ongoing rolling NDA review with the FDA and a National Priority Voucher, while a Phase 2b/3 PTSD trial (COMP202) is initiating under an accepted IND.
Compass Pathways reports new 26-week Phase 3 COMP006 data for its COMP360 psilocybin treatment in treatment-resistant depression and outlines an accelerated U.S. approval path. In nearly 600 participants, 39% of those receiving 25 mg achieved a clinically meaningful ≥25% reduction in MADRS scores by Week 6 and on average maintained benefit through at least Week 26, with additional dosing moving some into remission.
Serious adverse events were low and similar between arms over 26 weeks, at 6.3% in the 1 mg arm and 5.7% in the 25 mg arm, and most adverse events were transient on the day of dosing. A rolling NDA submission with the FDA is underway, with final submission expected in Q4 2026 and a potential U.S. launch in the first half of 2027, subject to FDA approval and DEA rescheduling.
COMPASS Pathways plc director Daphne Karydas received a grant of share options covering 21,110 ordinary shares. These options have an exercise price of $11.85 per share and were awarded at no cost as a compensation grant.
The options vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 Annual General Meeting of Shareholders, and they expire in 2036. Each ordinary share may be represented by one American Depositary Share.
COMPASS Pathways plc director Gino Santini received a grant of share options covering 30,158 Ordinary Shares. These options have an exercise price of $11.85 per share and expire on May 26, 2036. The options vest in full on the earlier of the first anniversary of the grant date or the company’s Annual General Meeting of Shareholders in 2027. Following this compensation award, Santini holds options for 30,158 shares, which may be exercised into Ordinary Shares that can be represented by American Depositary Shares on a one-for-one basis.
COMPASS Pathways plc director Justin D. Gover received a grant of share options over 21,110 Ordinary Shares. These options have an exercise price of $11.85 per share and expire on May 26, 2036. The shares underlying this option vest in full on the earlier of the first anniversary of the grant date or the company’s Annual General Meeting of Shareholders in 2027. The options are held directly and may be exercised for Ordinary Shares, which may be represented by American Depositary Shares, each currently equal to one Ordinary Share.